Cenix s Chris Echeverri on Leaving Academia to Run an RNAi Company

Sep 17, 2004

Premium

At A Glance

Name: Chris Echeverri

Position: Co-founder, CEO, CSO, Cenix Bioscience

Background: Postdoc, EMBL — 1998-1999; PhD, cell biology, University of Massachusetts Medical School — 1998; MS, biology, University of Ottawa — 1992; BS, biology, University of Ottawa — 1990

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Breakthrough Prize Winners Announced

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

Misuse of Genetic Research

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Not Quite the Ivy League Gene

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

This Week in Nature

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Featured White Papers

iPSC & CRISPR/Cas9 Technologies Enable Precise & Controlled Physiologically Relevant Disease Modeling for Basic & Applied Research

Tissue Section Imaging

In Vivo Validation of Optical Probes

Ex Vivo Imaging Quick Start Guide

Nov

05

Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov

15

Featured Webinar

Next-Generation Platforms for Strain Optimization: Reducing the Cost and Time for Commercializing Novel Biological Molecules

This webinar will discuss how Amyris, a biotechnology company that develops renewable products for a broad range of applications and industries, uses large-scale microbial engineering to support its manufacturing processes.

Main menu